- Home
- FLUX vs IMMX Comparison
FLUX vs IMMX Comparison
Compare FLUX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- IMMX
- Stock Information
- Founded
- FLUX N/A
- IMMX 2014
- Country
- FLUX United States
- IMMX United States
- Employees
- FLUX N/A
- IMMX N/A
- Industry
- FLUX Industrial Machinery/Components
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- FLUX Miscellaneous
- IMMX Health Care
- Exchange
- FLUX Nasdaq
- IMMX Nasdaq
- Market Cap
- FLUX 98.5M
- IMMX 82.6M
- IPO Year
- FLUX N/A
- IMMX 2021
- Fundamental
- Price
- FLUX $2.37
- IMMX $3.80
- Analyst Decision
- FLUX Strong Buy
- IMMX Strong Buy
- Analyst Count
- FLUX 2
- IMMX 1
- Target Price
- FLUX $6.00
- IMMX $8.00
- AVG Volume (30 Days)
- FLUX 989.0K
- IMMX 869.4K
- Earning Date
- FLUX 09-16-2025
- IMMX 11-07-2025
- Dividend Yield
- FLUX N/A
- IMMX N/A
- EPS Growth
- FLUX N/A
- IMMX N/A
- EPS
- FLUX N/A
- IMMX N/A
- Revenue
- FLUX $66,434,000.00
- IMMX N/A
- Revenue This Year
- FLUX $8.23
- IMMX N/A
- Revenue Next Year
- FLUX $24.72
- IMMX N/A
- P/E Ratio
- FLUX N/A
- IMMX N/A
- Revenue Growth
- FLUX 9.22
- IMMX N/A
- 52 Week Low
- FLUX $1.15
- IMMX $1.34
- 52 Week High
- FLUX $7.55
- IMMX $4.05
- Technical
- Relative Strength Index (RSI)
- FLUX 33.10
- IMMX 72.93
- Support Level
- FLUX $5.06
- IMMX $2.31
- Resistance Level
- FLUX $7.55
- IMMX $4.00
- Average True Range (ATR)
- FLUX 0.93
- IMMX 0.34
- MACD
- FLUX -0.49
- IMMX 0.08
- Stochastic Oscillator
- FLUX 2.45
- IMMX 85.63
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.